CY2013037I1 - Ανταγωνιστης υποδοχεα της αγγειοτενσινης ιι για τη θεραπευτικη αγωγη συστημικων νοσων σε γατες - Google Patents

Ανταγωνιστης υποδοχεα της αγγειοτενσινης ιι για τη θεραπευτικη αγωγη συστημικων νοσων σε γατες

Info

Publication number: CY2013037I1
Authority: CY; Cyprus
Prior art keywords: angiotensin; cats; treatment; receptor antagonist; systemic disease
Prior art date: 2006-10-06

Application number

CY2013037C

Other languages

English (en)

Other versions

CY2013037I2 (el

Original Assignee

Boehringer Ingelheim Vetmedica Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-06

Filing date

2013-09-18

Publication date

2015-11-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37744125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2013037(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-09-18 Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh

2015-11-04 Publication of CY2013037I1 publication Critical patent/CY2013037I1/el

2015-11-04 Publication of CY2013037I2 publication Critical patent/CY2013037I2/el

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CY2013037C 2006-10-06 2013-09-18 Ανταγωνιστης, υποδοχεα της αγγειοτενσινης ιι για τη θεραπευτικη αγωγη συστημικων νοσων σε γατες CY2013037I2 (el)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP06121905A EP1908469A1 (en)	2006-10-06	2006-10-06	Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
PCT/EP2007/060531 WO2008040774A2 (en)	2006-10-06	2007-10-04	Angiotensin ii receptor antagonist for the treatment of systemic diseases in cats
EP07820908.7A EP2086535B1 (en)	2006-10-06	2007-10-04	Angiotensin ii receptor antagonist for the treatment of systemic diseases in cats

Publications (2)

Publication Number	Publication Date
CY2013037I1 true CY2013037I1 (el)	2015-11-04
CY2013037I2 CY2013037I2 (el)	2015-11-04

Family

ID=37744125

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CY20131100712T CY1114266T1 (el)	2006-10-06	2013-08-21	Ανταγωνιστης υποδοχεα της αγγειοτενσινης ιι για τη θεραπευτικη αγωγη συστημικων νοσων σε γατες
CY2013037C CY2013037I2 (el)	2006-10-06	2013-09-18	Ανταγωνιστης, υποδοχεα της αγγειοτενσινης ιι για τη θεραπευτικη αγωγη συστημικων νοσων σε γατες

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CY20131100712T CY1114266T1 (el)	2006-10-06	2013-08-21	Ανταγωνιστης υποδοχεα της αγγειοτενσινης ιι για τη θεραπευτικη αγωγη συστημικων νοσων σε γατες

Country Status (25)

Country	Link
US (5)	US8772278B2 (el)
EP (5)	EP1908469A1 (el)
JP (5)	JP5425631B2 (el)
KR (2)	KR101456151B1 (el)
CN (6)	CN105148272A (el)
AR (1)	AR063155A1 (el)
BR (4)	BR122013019534A2 (el)
CA (1)	CA2665435C (el)
CL (2)	CL2007002897A1 (el)
CO (1)	CO6180425A2 (el)
CY (2)	CY1114266T1 (el)
DK (4)	DK2420233T3 (el)
ES (4)	ES2562182T3 (el)
HR (1)	HRP20130696T1 (el)
HU (4)	HUE027280T2 (el)
LU (1)	LU92282I2 (el)
MX (4)	MX360147B (el)
NL (1)	NL300616I2 (el)
NZ (3)	NZ597648A (el)
PL (4)	PL2420231T3 (el)
PT (1)	PT2086535E (el)
SI (1)	SI2086535T1 (el)
TW (3)	TWI539949B (el)
WO (1)	WO2008040774A2 (el)
ZA (1)	ZA200901218B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1908469A1 (en) *	2006-10-06	2008-04-09	Boehringer Ingelheim Vetmedica Gmbh	Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
TW200920371A (en) *	2007-08-29	2009-05-16	Orion Corp	A combination treatment
WO2010097501A2 (en) *	2009-02-26	2010-09-02	Orion Corporation	A combination treatment
DK2432452T3 (en)	2009-05-20	2016-10-10	Boehringer Ingelheim Vetmedica Gmbh	Pharmaceutically telmisartan drink solution
CN102283832B (zh) *	2011-09-09	2013-04-10	南京正宽医药科技有限公司	一种预防或治疗高血压肥胖患者的药物组合物及用途
SG11201407200TA (en) *	2012-05-18	2014-12-30	Luoda Pharma Pty Ltd	Liquid formulation
DE102012018903A1 (de)	2012-09-26	2014-03-27	Elisabeth Kurth	Brustglocke für die manuelle Laktation von Milch aus der weiblichen Brust
CN105233288A (zh) *	2015-09-28	2016-01-13	青岛云天生物技术有限公司	一种治疗或预防肥胖型高血压的药物组合物及其用途
JP6800633B2 (ja) *	2016-07-04	2020-12-16	株式会社カネカ	非ヒト動物において腎機能の低下を抑制する方法
LT3648761T (lt) *	2017-07-07	2024-06-10	Boehringer Ingelheim Vetmedica Gmbh	Telmisartanas, skirtas kačių hipertenzijos profilaktikai arba gydymui
AU2020310059A1 (en) *	2019-07-09	2022-02-17	Boehringer Ingelheim Vetmedica Gmbh	Telmisartan for the treatment of hypertension in dogs
WO2024240633A1 (en)	2023-05-24	2024-11-28	Boehringer Ingelheim Vetmedica Gmbh	Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1023027B (de)	1953-07-10	1958-01-23	Hoffmann La Roche	Verfahren zur Herstellung von Polyendialdehyden
JPS5671074A (en)	1979-11-12	1981-06-13	Takeda Chem Ind Ltd	1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4448778A (en)	1981-08-03	1984-05-15	Ici Americas Inc.	Maltitol containing gel base systems
CA1334092C (en)	1986-07-11	1995-01-24	David John Carini	Angiotensin ii receptor blocking imidazoles
US4880804A (en)	1988-01-07	1989-11-14	E. I. Du Pont De Nemours And Company	Angiotensin II receptor blocking benzimidazoles
US5015651A (en)	1988-01-07	1991-05-14	E. I. Du Pont De Nemours And Company	Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en)	1988-01-07	1996-04-09	David John Carini	Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
IE70593B1 (en)	1989-09-29	1996-12-11	Eisai Co Ltd	Biphenylmethane derivative the use of it and pharmacological compositions containing same
IL97219A (en)	1990-02-19	1995-12-08	Ciba Geigy Ag	Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them
PT97078B (pt)	1990-03-20	1997-07-31	Sanofi Sa	Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
US5196444A (en)	1990-04-27	1993-03-23	Takeda Chemical Industries, Ltd.	1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IE912956A1 (en)	1990-09-10	1992-03-11	Abbott Lab	Angiotensin ii receptor antagonists
US6028091A (en)	1990-12-14	2000-02-22	Smithkline Beecham Plc	Medicament
GB9027210D0 (en)	1990-12-14	1991-02-06	Smithkline Beecham Plc	Medicaments
US5614519A (en)	1991-02-06	1997-03-25	Karl Thomae Gmbh	(1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
SI9210098B (sl)	1991-02-06	2000-06-30	Dr. Karl Thomae	Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5196537A (en)	1991-03-21	1993-03-23	G. D. Searle & Co.	5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en)	1991-05-16	1991-07-03	Glaxo Group Ltd	Chemical compounds
EP0636027B1 (en)	1992-04-13	1999-07-07	Zeneca Limited	Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
JP3862295B2 (ja) *	1993-09-30	2006-12-27	独立行政法人理化学研究所	抗肥満剤
WO1995026188A1 (en)	1994-03-29	1995-10-05	Merck & Co., Inc.	Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
MX9707683A (es) *	1995-04-07	1997-12-31	Novartis Ag	Composiciones de combinacion que contienen benazepril o benazeprilat y valsartan.
DE69712338T2 (de) *	1996-06-24	2002-11-07	Merck & Co., Inc.	Zusammensetzung auf basis von enalapril und losartan
ZA991706B (en)	1998-03-04	2000-10-03	Takeda Chemical Industries Ltd	Sustained-release preparation for Aii Antagonist, production and use thereof.
JPH11315034A (ja) *	1998-03-04	1999-11-16	Takeda Chem Ind Ltd	アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途
US6204281B1 (en) *	1998-07-10	2001-03-20	Novartis Ag	Method of treatment and pharmaceutical composition
DE19901921C2 (de)	1999-01-19	2001-01-04	Boehringer Ingelheim Pharma	Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels
US6358986B1 (en)	1999-01-19	2002-03-19	Boehringer Ingelheim Pharma Kg	Polymorphs of telmisartan
DE10018401A1 (de) *	2000-04-13	2001-10-25	Boehringer Ingelheim Pharma	Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
WO2002030400A1 (fr) *	2000-10-06	2002-04-18	Takeda Chemical Industries, Ltd.	Preparations solides
JP2005501815A (ja)	2001-05-14	2005-01-20	メルク　エンド　カムパニー　インコーポレーテッド	治療方法
US20040219208A1 (en) *	2001-08-03	2004-11-04	Ryu Kawamura	Sustained-release medicines
DE10153737A1 (de)	2001-10-31	2003-05-28	Boehringer Ingelheim Pharma	Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US6737432B2 (en)	2001-10-31	2004-05-18	Boehringer Ingelheim Pharma Kg	Crystalline form of telmisartan sodium
MXPA04011428A (es) *	2002-05-17	2005-02-14	Novartis Ag	Combinacion de bloqueador del receptor de angiotensina ii y bloqueador-beta para la prevencion secundaria de infarto de miocardio.
US7232828B2 (en)	2002-08-10	2007-06-19	Bethesda Pharmaceuticals, Inc.	PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
JP2006516020A (ja) *	2002-08-28	2006-06-15	キュリスインコーポレイテッド	慢性腎不全の治療におけるモルフォゲン及びａｃｅ阻害薬の共投与
US8980870B2 (en) *	2002-09-24	2015-03-17	Boehringer Ingelheim International Gmbh	Solid telmisartan pharmaceutical formulations
DE10244681A1 (de)	2002-09-24	2004-04-08	Boehringer Ingelheim International Gmbh	Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
DE10335027A1 (de)	2003-07-31	2005-02-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von Angiotensin II Rezeptor Antagonisten
WO2005070463A2 (en) *	2004-01-12	2005-08-04	Sepracor, Inc.	Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use
DE102004008804A1 (de) *	2004-02-20	2005-09-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Mehrschichttablette
EP1579862A1 (en) *	2004-03-25	2005-09-28	Boehringer Ingelheim Vetmedica Gmbh	Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
WO2005123070A1 (en) *	2004-06-09	2005-12-29	Fibrogen, Inc.	Dual blockade of renin-angiotensin system reduces connective tissue growth factor levels in diabetic nephropathy
CN1602960A (zh) *	2004-07-23	2005-04-06	海南国栋药物研究所有限公司	一种防治心脑血管病及糖尿病等代谢综合症的复合制剂
CN100364532C (zh) *	2004-09-30	2008-01-30	江苏恒瑞医药股份有限公司	包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物
EP1814527B2 (en) *	2004-11-05	2020-11-18	Boehringer Ingelheim International GmbH	Bilayer tablet comprising telmisartan and amlodipine
CN1813707A (zh) *	2004-12-01	2006-08-09	鲁南制药集团股份有限公司	用于治疗高血压的含有单硝酸异山梨酯的药物组合物
US20070026026A1 (en) *	2005-08-01	2007-02-01	David Delmarre	Oral liquid losartan compositions
EP1908469A1 (en) *	2006-10-06	2008-04-09	Boehringer Ingelheim Vetmedica Gmbh	Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP1970053A1 (en)	2007-03-14	2008-09-17	Boehringer Ingelheim Pharma GmbH & Co. KG	Pharmaceutical composition
DK2432452T3 (en)	2009-05-20	2016-10-10	Boehringer Ingelheim Vetmedica Gmbh	Pharmaceutically telmisartan drink solution

2006
- 2006-10-06 EP EP06121905A patent/EP1908469A1/en not_active Ceased
2007
- 2007-10-04 NZ NZ597648A patent/NZ597648A/xx unknown
- 2007-10-04 BR BRBR122013019534-3A patent/BR122013019534A2/pt not_active Application Discontinuation
- 2007-10-04 NZ NZ576109A patent/NZ576109A/en unknown
- 2007-10-04 ES ES11186078.9T patent/ES2562182T3/es active Active
- 2007-10-04 CN CN201510336736.0A patent/CN105148272A/zh active Pending
- 2007-10-04 BR BRPI0718041 patent/BRPI0718041A2/pt not_active Application Discontinuation
- 2007-10-04 PL PL11186070T patent/PL2420231T3/pl unknown
- 2007-10-04 CN CN201811093737.7A patent/CN109125730A/zh active Pending
- 2007-10-04 JP JP2009530883A patent/JP5425631B2/ja active Active
- 2007-10-04 CN CN202111463480.1A patent/CN114344293B/zh active Active
- 2007-10-04 DK DK11186080.5T patent/DK2420233T3/en active
- 2007-10-04 ES ES07820908T patent/ES2425482T3/es active Active
- 2007-10-04 CN CN201210056647.7A patent/CN102580095B/zh active Active
- 2007-10-04 CN CN2007800374949A patent/CN101522191B/zh active Active
- 2007-10-04 DK DK07820908.7T patent/DK2086535T3/da active
- 2007-10-04 PT PT78209087T patent/PT2086535E/pt unknown
- 2007-10-04 PL PL11186080T patent/PL2420233T3/pl unknown
- 2007-10-04 EP EP11186078.9A patent/EP2420232B1/en active Active
- 2007-10-04 HR HRP20130696TT patent/HRP20130696T1/hr unknown
- 2007-10-04 BR BRBR122013019535-1A patent/BR122013019535A2/pt not_active Application Discontinuation
- 2007-10-04 KR KR1020097009113A patent/KR101456151B1/ko active Active
- 2007-10-04 NZ NZ609533A patent/NZ609533A/en unknown
- 2007-10-04 ES ES11186080.5T patent/ES2567041T3/es active Active
- 2007-10-04 MX MX2013004348A patent/MX360147B/es unknown
- 2007-10-04 CN CN2011104188656A patent/CN102512678A/zh active Pending
- 2007-10-04 KR KR1020147014825A patent/KR101529541B1/ko active Active
- 2007-10-04 PL PL11186078T patent/PL2420232T3/pl unknown
- 2007-10-04 WO PCT/EP2007/060531 patent/WO2008040774A2/en not_active Ceased
- 2007-10-04 EP EP07820908.7A patent/EP2086535B1/en active Active
- 2007-10-04 MX MX2013004349A patent/MX360150B/es unknown
- 2007-10-04 DK DK11186078.9T patent/DK2420232T3/en active
- 2007-10-04 DK DK11186070.6T patent/DK2420231T3/en active
- 2007-10-04 BR BRBR122013019533-5A patent/BR122013019533A2/pt not_active Application Discontinuation
- 2007-10-04 HU HUE11186078A patent/HUE027280T2/en unknown
- 2007-10-04 CA CA2665435A patent/CA2665435C/en active Active
- 2007-10-04 HU HUE11186070A patent/HUE027399T2/en unknown
- 2007-10-04 MX MX2009002340A patent/MX2009002340A/es active IP Right Grant
- 2007-10-04 SI SI200731289T patent/SI2086535T1/sl unknown
- 2007-10-04 ES ES11186070.6T patent/ES2565519T3/es active Active
- 2007-10-04 MX MX2013004347A patent/MX360148B/es unknown
- 2007-10-04 PL PL07820908T patent/PL2086535T3/pl unknown
- 2007-10-04 EP EP11186070.6A patent/EP2420231B1/en active Active
- 2007-10-04 EP EP11186080.5A patent/EP2420233B1/en active Active
- 2007-10-05 CL CL200702897A patent/CL2007002897A1/es unknown
- 2007-10-05 TW TW102114897A patent/TWI539949B/zh active
- 2007-10-05 TW TW096137618A patent/TWI415605B/zh active
- 2007-10-05 TW TW102133689A patent/TWI539950B/zh active
- 2007-10-05 US US11/973,250 patent/US8772278B2/en active Active
- 2007-10-09 AR ARP070104427A patent/AR063155A1/es unknown
2009
- 2009-02-20 ZA ZA200901218A patent/ZA200901218B/xx unknown
- 2009-04-06 CO CO09035442A patent/CO6180425A2/es not_active Application Discontinuation
2012
- 2012-05-24 CL CL2012001349A patent/CL2012001349A1/es unknown
2013
- 2013-03-13 US US13/799,768 patent/US9308197B2/en active Active
- 2013-08-01 JP JP2013160676A patent/JP5899165B2/ja active Active
- 2013-08-01 JP JP2013160675A patent/JP6151123B2/ja active Active
- 2013-08-21 CY CY20131100712T patent/CY1114266T1/el unknown
- 2013-09-18 NL NL300616C patent/NL300616I2/nl unknown
- 2013-09-18 CY CY2013037C patent/CY2013037I2/el unknown
- 2013-09-19 LU LU92282C patent/LU92282I2/fr unknown
- 2013-10-21 HU HUS1300062C patent/HUS1300062I1/hu unknown
2014
- 2014-06-02 US US14/293,472 patent/US9585873B2/en active Active
2015
- 2015-12-07 JP JP2015238531A patent/JP2016094436A/ja active Pending
2017
- 2017-01-20 US US15/411,062 patent/US9949954B2/en active Active
- 2017-03-06 JP JP2017042000A patent/JP6337170B2/ja active Active
2018
- 2018-03-08 US US15/915,817 patent/US10357479B2/en active Active
- 2018-11-08 HU HUS1800044C patent/HUS1800044I1/hu unknown

Also Published As

Publication number	Publication date
CL2012001349A1 (es)	2012-10-12
US20080146543A1 (en)	2008-06-19
HUE027399T2 (en)	2016-09-28
EP2420233A2 (en)	2012-02-22
ES2565519T3 (es)	2016-04-05
TWI539950B (zh)	2016-07-01
MX2009002340A (es)	2009-03-23
HUS1800044I1 (hu)	2018-12-28
CA2665435A1 (en)	2008-04-10
EP2420232B1 (en)	2016-01-06
US9308197B2 (en)	2016-04-12
US20130190373A1 (en)	2013-07-25
EP2420231A2 (en)	2012-02-22
BR122013019533A2 (pt)	2015-07-14
CN102512678A (zh)	2012-06-27
JP5899165B2 (ja)	2016-04-06
KR20140088601A (ko)	2014-07-10
TW201332547A (zh)	2013-08-16
PL2086535T3 (pl)	2013-10-31
US20170128423A1 (en)	2017-05-11
PL2420231T3 (pl)	2016-07-29
KR20090080954A (ko)	2009-07-27
US8772278B2 (en)	2014-07-08
NZ576109A (en)	2012-02-24
CO6180425A2 (es)	2010-07-19
US9585873B2 (en)	2017-03-07
JP2010505796A (ja)	2010-02-25
LU92282I2 (fr)	2013-11-19
ES2567041T3 (es)	2016-04-19
MX360150B (es)	2018-10-24
US20140288138A1 (en)	2014-09-25
TW201402115A (zh)	2014-01-16
PT2086535E (pt)	2013-08-22
CY2013037I2 (el)	2015-11-04
CN101522191A (zh)	2009-09-02
AU2007304216A1 (en)	2008-04-10
NL300616I2 (el)	2016-06-01
CL2007002897A1 (es)	2008-03-07
KR101529541B1 (ko)	2015-06-17
MX360148B (es)	2018-10-24
HUE027280T2 (en)	2016-09-28
EP2420232A3 (en)	2012-05-02
ES2562182T3 (es)	2016-03-02
KR101456151B1 (ko)	2014-11-04
JP2013216709A (ja)	2013-10-24
PL2420232T3 (pl)	2016-06-30
EP2420231B1 (en)	2016-01-13
JP2013216708A (ja)	2013-10-24
DK2420231T3 (en)	2016-04-11
DK2086535T3 (da)	2013-07-22
BR122013019534A2 (pt)	2015-07-14
MX360147B (es)	2018-10-24
LU92282I9 (el)	2019-01-17
DK2420233T3 (en)	2016-04-11
JP5425631B2 (ja)	2014-02-26
EP2420231A3 (en)	2012-04-11
JP6151123B2 (ja)	2017-06-21
SI2086535T1 (sl)	2013-09-30
US9949954B2 (en)	2018-04-24
TWI539949B (zh)	2016-07-01
JP2017122115A (ja)	2017-07-13
US20180193317A1 (en)	2018-07-12
BR122013019535A2 (pt)	2015-07-14
CN102580095B (zh)	2015-12-09
EP1908469A1 (en)	2008-04-09
CN114344293A (zh)	2022-04-15
HUS1300062I1 (hu)	2013-11-28
DK2420232T3 (en)	2016-03-07
US10357479B2 (en)	2019-07-23
CY1114266T1 (el)	2015-11-04
WO2008040774A3 (en)	2008-07-10
PL2420233T3 (pl)	2016-07-29
EP2086535B1 (en)	2013-05-22
HRP20130696T1 (hr)	2013-09-30
JP2016094436A (ja)	2016-05-26
CN109125730A (zh)	2019-01-04
AR063155A1 (es)	2008-12-30
JP6337170B2 (ja)	2018-06-06
ES2425482T3 (es)	2013-10-15
EP2086535A2 (en)	2009-08-12
NZ597648A (en)	2013-05-31
CA2665435C (en)	2016-03-29
CN105148272A (zh)	2015-12-16
EP2420233B1 (en)	2016-01-13
EP2420233A3 (en)	2012-04-18
AU2007304216B2 (en)	2013-06-13
NZ609533A (en)	2014-08-29
CN102580095A (zh)	2012-07-18
TWI415605B (zh)	2013-11-21
CN114344293B (zh)	2024-04-19
CN101522191B (zh)	2012-05-16
EP2420232A2 (en)	2012-02-22
BRPI0718041A2 (pt)	2015-05-12
TW200831078A (en)	2008-08-01
WO2008040774A2 (en)	2008-04-10
ZA200901218B (en)	2010-03-31

Publication	Publication Date	Title
CY2013037I1 (el)	2015-11-04	Ανταγωνιστης υποδοχεα της αγγειοτενσινης ιι για τη θεραπευτικη αγωγη συστημικων νοσων σε γατες
CY2024028I1 (el)	2025-09-26	Ενα διφαινυλοσουλφοναμιδιο ανταγωνιστης του υποδοχεα της ενδοθηλινης και της αγγειοτενσινης ii για τη θεραπεια της σπειραματοσκληρυνσης
LTC2340828I2 (lt)	2024-05-10	Angiotenzino receptorių antagonisto ir nep inhibitoriaus farmaciniai deriniai
LTC1776142I2 (lt)	2022-07-11	IL-17 antagonistiniai antikūnai
BRPI0716893A2 (pt)	2014-05-06	Forma de dosagem sólida de olmesartan medoxomila e anlodipina
DK1986650T3 (da)	2012-08-13	Manipulationssikre doserignsformer
DK2081951T3 (da)	2010-08-09	Progesteron-receptorantagonister
DK2343071T3 (da)	2013-05-13	Farmaceutiske doseringsformer
HRP20151108T1 (xx)	2015-11-20	Antagonisti nogo-receptora
EP2004654A4 (en)	2010-03-24	Kinase Antagonists
BRPI0616703A2 (pt)	2016-09-06	forma de dosagem farmacêutica
PL2468290T3 (pl)	2015-08-31	Antagoniści aktywiny-ActRII do stosowania w leczeniu niedokrwistości
HUE058231T2 (hu)	2022-07-28	Eszköz gastrooesophagealis reflux betegség kezelésére
EP2145185A4 (en)	2010-06-02	Multi-analyte assay
ATE419540T1 (de)	2009-01-15	Blitzerkennung
DK2144905T3 (da)	2013-03-11	Terapeutiske midler
DK1849356T3 (da)	2013-03-04	Sammenklappelig fiskefælde
ATE382034T1 (de)	2008-01-15	Hydroisoindolin-tachykininrezeptorantagonisten
HRP20160950T1 (hr)	2016-10-07	Polimorfi antagonista mglur5 receptora
HUE058307T2 (hu)	2022-07-28	GLP-1 receptor antagonista veleszületett hiperinzulinizmus kezelésében történõ használatra
ATE524972T1 (de)	2011-10-15	Poly-tlr-antagonist
FR2906556B1 (fr)	2008-12-05	Abri
ITVI20060364A1 (it)	2008-06-28	Ciotola multiuso portatile per animali
ITVI20060365A1 (it)	2008-06-28	Ciotola multiuso portatile per animali
FR2906440B1 (fr)	2010-06-11	Piege selectif pour animaux